Quantcast
Last updated on April 21, 2014 at 8:55 EDT

Latest Cystic Fibrosis Foundation Stories

2010-05-20 08:30:00

Patients Over 40 Once Unheard-of Now a Growing Segment of the Population An emerging population of middle-aged cystic fibrosis patients contains significantly more females and includes a large proportion of patients who lived for decades without a diagnosis or specialized care, according to research published by researchers at National Jewish Health. The comprehensive analysis of this over-40 cohort, published online May 20 in the American Journal of Respiratory and Critical Care, may help...

2010-05-19 09:51:00

Cystic Fibrosis Foundation Drug Development Model Spawns More Than 30 Promising Therapies BETHESDA, Md., May 19 /PRNewswire-USNewswire/ -- National Institutes of Health (NIH) Director Francis S. Collins, M.D., Ph.D., will lead a briefing on Capitol Hill Thursday, May 20, to discuss how funding for medical research at the NIH can be used more quickly to create new therapies for patients and save lives. Since being appointed director of the NIH, Collins has stressed the importance of...

2010-05-13 13:03:00

Tens of Thousands to Participate during National Cystic Fibrosis Awareness Month BETHESDA, Md., May 13 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation announced today that more than 200 cities will host GREAT STRIDES walks May 15-16. GREAT STRIDES is a national fundraiser benefiting critical cystic fibrosis (CF) research, education and care programs. GREAT STRIDES is in its 22nd year and seeks to raise about $40 million in 2010. Funds raised through GREAT STRIDES have helped...

2010-05-03 06:05:00

Eurand Donates $300,000 as Title Sponsor of ZENPEP(R) CF Cycle for Life BETHESDA, Md., May 3 /PRNewswire-USNewswire/ -- Thousands of cyclists will take to the streets this summer and fall as the Cystic Fibrosis Foundation launches a new cycling tour in 18 cities across the country to support research to find new therapies and a cure for cystic fibrosis. The tour series, known as ZENPEP® CF Cycle for Life, begins in San Francisco on June 26. The event's title sponsor is...

b0ca0f0efb6b4f75bcb1fbf788af7d4d1
2010-04-29 08:47:22

Aided by a new experimental model, scientists are a step closer to understanding how cystic fibrosis (CF) causes lung disease in people with the condition. The findings, published online April 28 in the journal Science Translational Medicine, could help improve treatments for lung disease, which causes most of the deaths and disability among people with CF. In particular, the study by a University of Iowa research team and colleagues at University of Missouri appears to answer a long-standing...

2010-04-14 07:00:00

BALTIMORE, April 14 /PRNewswire/ -- Metastorm, a leading provider of Business Process Management (BPM), Business Process Analysis (BPA), and Enterprise Architecture (EA) software for aligning strategy with execution, today announced its national sponsorship of the Cystic Fibrosis Foundation's Great Strides Walk series - the foundation's largest national fundraising event. Great Strides Walks take place in May and June and are held in locations across the United States. Metastorm is...

2010-03-25 12:02:00

BETHESDA, March 25 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation announced today that its Facebook page has surpassed 60,000 fans--double the number of people in the United States who have cystic fibrosis, a rare and fatal genetic disease. This rapid growth may reflect the need for people with CF to come together and exchange information in a setting that does not put their health at risk. People with CF cannot socialize in proximity to each other without risking germ...

2010-03-11 08:00:00

WAYNE, N.J., March 11 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration (FDA) for ciprofloxacin dry powder inhaler (DPI) for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients. A similar designation has already been granted by the European Medicines Agency. Ciprofloxacin DPI is an investigational drug-device combination that combines...

2010-02-23 10:22:00

MONTEREY, Calif., Feb. 23 /PRNewswire/ -- Altera, which uses eFlow Technology, was cleared to market today by the FDA as the first drug-specific nebulizer for use in the treatment of patients with cystic fibrosis and has been specifically developed to deliver Gilead Sciences' Cayston (aztreonam for inhalation solution) 75 mg. Cayston is a new inhaled antibiotic that received marketing approval from the U.S. Food and Drug Administration (FDA) yesterday as a treatment to improve respiratory...

2010-02-22 20:48:00

CF Foundation's $1 Million Investment Helped Drug Known as Cayston(R) Become a Reality BETHESDA, Md., Feb. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help...